cladribine has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baytas, SN; Cetin Atalay, R; Eren, F; Hawash, MM; Kahraman, DC | 1 |
| Geisen, FH; Graziadei, I; Kelly, T; Konwalinka, G; Schirmer, M; Vogel, W | 1 |
2 other study(ies) available for cladribine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Chalcone; G2 Phase; Humans; Liver Neoplasms; Pyrazoles; Structure-Activity Relationship | 2017 |
Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cladribine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Liver Neoplasms; Nucleosides; Tumor Cells, Cultured | 1998 |